VIBRANTZ-TECHNOLOGIES
19.12.2023 08:46:34 CET | Business Wire | Press release
Eramet and Vibrantz Technologies today announced a 10-year agreement whereby Eramet will supply Vibrantz with manganese ore, an essential raw material used in Vibrantz’s portfolio of manganese technologies for lithium-ion battery and other applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218880208/en/
Another significant step in both companies’ commitments to corporate social responsibility and supporting the transition to a lower emission future, the agreement builds on the 20-year Eramet-Vibrantz partnership to create a reliable pathway for Vibrantz’s manganese sulfate manufacture used in the production of electric vehicle (EV) batteries. Eramet’s manganese ore will be sourced from its Gabon mine which will undertake the Initiative for Responsible Mining Assurance’s (IRMA) audit process to align its operations with international best practices.
“This agreement confirms Eramet's ability to satisfy and win the loyalty of its customers and partners by supplying quality ore produced under responsible conditions,” said Christel Bories, Eramet Chairman and CEO. “Eramet is particularly well positioned to become a key responsible player in the battery value chain through our long-life, high-grade deposits in strategic metals, such as manganese in Gabon, lithium in Argentina at Centenario, and nickel and cobalt in Indonesia at Weda Bay.” Bories added that Eramet seeks to have all of its sites IRMA audited by 2026.
This news comes on the heels of Vibrantz’s announcement that it is constructing a pilot facility to process battery-grade high-purity manganese sulfate (HPMSM) at its Tampico, Mexico, site.
“As Vibrantz advances our commitment to becoming a sustainable and world-class specialty chemicals and materials solutions provider, we value our enduring partnership with Eramet,” said D. Michael Wilson, Vibrantz President and CEO. “This agreement allows Vibrantz to leverage both companies’ 50 years of combined expertise in manganese chemicals as we work to make environmentally friendly vehicles a growing reality for millions of consumers.” Wilson also said the company continues to receive positive market reception of its recent HPMSM capacity investments from battery producers and automotive original equipment manufacturers.
Explore Eramet’s activities here and learn more about Vibrantz’s trusted manganese technologies utilized in battery, agriculture, construction, electronics and water treatment end-use markets.
About Eramet
Eramet transforms the Earth’s mineral resources to provide sustainable and responsible solutions to the growth of the industry and to the challenges of the energy transition. Its employees are committed to this through their civic and contributory approach in all the countries where the mining and metallurgical group is present. Eramet recovers and develops metals essential to the construction of a more sustainable world. Fully committed to the era of metals, Eramet’s ambition is to become a reference for the responsible transformation of the Earth’s mineral resources for living well together.
Visit www.eramet.com.
About Vibrantz Technologies
Vibrantz is a leading global provider of specialty chemicals and materials whose purpose is to bring color, performance and vibrancy to life. Serving over 11,000 customers, our products and technologies serve a wide array of applications and make their way into myriad consumer products. With key competencies in particle engineering, glass and ceramic science and color technology, Vibrantz has leading positions in specialty mineral and chemical additives for batteries, electronic components and construction; pigments for paints and coatings, thermoset plastics and thermoplastics; and high-performance glass coatings and porcelain enamel solutions. Headquartered in Houston, Texas, the company employs approximately 5,000 people and operates 65 manufacturing sites across six continents.
Visit vibrantz.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231218880208/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom